Clinical pharmacogenetics implementation consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 6, 2014, Pages 592-597

  Clancy, J P ^a,b   Johnson, S G ^c,d   Yee, S W ^e   Mcdonagh, E M ^f   Caudle, K E ^g   Klein, T E ^f   Cannavo, M ^g   Giacomini, K M ^e  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d Clinical Pharmacy Services   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^g ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR;

ARTICLE; CYSTIC FIBROSIS; DRUG EFFECT; GENE MUTATION; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HUMAN; IN VITRO STUDY; INCIDENTAL FINDING; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS;

AMINOPHENOLS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENETIC TESTING; GUIDELINES AS TOPIC; HUMANS; PHARMACOGENETICS; QUINOLONES; RISK ASSESSMENT;

EID: 84901244735     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.54     Document Type: Article

References (40)

1. Rowe, S.M., Miller, S. & Sorscher, E.J. Cystic fibrosis. N. Engl. J. Med. 352, 1992-2001 (2005
2. Rogan, M.P., Stoltz, D.A. & Hornick, D.B. Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment. Chest 139, 1480-1490 (2011
3. Rommens, J.M. et al. Identification of the cystic fibrosis gene: Chromosome walking and jumping. Science 245, 1059-1065 (1989
4. Riordan, J.R. et al. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science 245, 1066-1073 (1989
5. Riordan, J.R. CFTR function and prospects for therapy. Annu. Rev. Biochem. 77, 701-726 (2008
6. Anderson, M.P. et al. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science 253, 202-205 (1991
7. Welsh, M.J. & Smith, J.J. cAMP stimulation of HCO3-secretion across airway epithelia. JOP 2, 291-293 (2001
8. Tang, L., Fatehi, M. & Linsdell, P. Mechanism of direct bicarbonate transport by the CFTR anion channel. J. Cyst. Fibros. 8, 115-121 (2009
9. Schwiebert, E.M., Benos, D.J., Egan, M.E., Stutts, M.J. & Guggino, W.B. CFTR is a conductance regulator as well as a chloride channel. Physiol. Rev. 79, S145-S166 (1999
10. Hudson, V.M. Rethinking cystic fibrosis pathology: The critical role of abnormal reduced glutathione (GSH) transport caused by CFTR mutation. Free Radic. Biol. Med. 30, 1440-1461 (2001
11. Moskwa, P. et al. A novel host defense system of airways is defective in cystic fibrosis. Am. J. Respir. Crit. Care Med. 175, 174-183 (2007
12. Stutts, M.J. et al. CFTR as a cAMP-dependent regulator of sodium channels. Science 269, 847-850 (1995
13. Engelhardt, J.F., Zepeda, M., Cohn, J.A., Yankaskas, J.R. & Wilson, J.M. Expression of the cystic fibrosis gene in adult human lung. J. Clin. Invest. 93, 737-749 (1994
14. Joo, N.S., Irokawa, T., Robbins, R.C. & Wine, J.J. Hyposecretion, not hyperabsorption, is the basic defect of cystic fibrosis airway glands. J. Biol. Chem. 281, 7392-7398 (2006
15. Matsui, H. et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 95, 1005-1015 (1998
16. Matsui, H., Randell, S.H., Peretti, S.W., Davis, C.W. & Boucher, R.C. Coordinated clearance of periciliary liquid and mucus from airway surfaces. J. Clin. Invest. 102, 1125-1131 (1998
17. Boucher, R.C. Airway surface dehydration in cystic fibrosis: Pathogenesis and therapy. Annu. Rev. Med. 58, 157-170 (2007
18. Agundez, J.A., Golka, K., Martinez, C., Selinski, S., Blaszkewicz, M. & Garcia-Martin, E. Unraveling ambiguous NAT2 genotyping data. Clin. Chem. 54, 1390-1394 (2008
19. Donaldson, S.H. & Boucher, R.C. Sodium channels and cystic fibrosis. Chest 132, 1631-1636 (2007
20. Gustafsson, J.K. et al. Bicarbonate and functional CFTR channel are required for proper mucin secretion and link cystic fibrosis with its mucus phenotype. J. Exp. Med. 209, 1263-1272 (2012
21. Pezzulo, A.A. et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 487, 109-113 (2012
22. Banner, K.H. et al. Highlights of a workshop to discuss targeting inflammation in cystic fibrosis. J. Cyst. Fibros. 8, 1-8 (2009
23. Sagel, S.D., Chmiel, J.F. & Konstan, M.W. Sputum biomarkers of inflammation in cystic fibrosis lung disease. Proc. Am. Thorac. Soc. 4, 406-417 (2007
24. Clancy, J.P. & Jain, M. Personalized medicine in cystic fibrosis: Dawning of a new era. Am. J. Respir. Crit. Care Med. 186, 593-597 (2012
25. Pilewski, J.M. & Frizzell, R.A. Role of CFTR in airway disease. Physiol. Rev. 79, S215-S255 (1999
26. Logan, J. et al. Cystic fibrosis transmembrane conductance regulator mutations that disrupt nucleotide binding. J. Clin. Invest. 94, 228-236 (1994
27. Van Goor, F. et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc. Natl. Acad. Sci. USA 106, 18825-18830 (2009
28. Eckford, P.D., Li, C., Ramjeesingh, M. & Bear, C.E. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J. Biol. Chem. 287, 36639-36649 (2012
29. Ramsey, B.W. et al.; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 365, 1663-1672 (2011
30. Davies, J.C. et al.; VX08-770-103 (ENVISION) Study Group. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am. J. Respir. Crit. Care Med. 187, 1219-1225 (2013
31. Flume, P.A. et al.; VX 08-770-104 Study Group. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 142, 718-724 (2012
32. Yu, H. et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J. Cyst. Fibros. 11, 237-245 (2012
33. Van Goor, F. et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc. Natl. Acad. Sci. USA 108, 18843-18848 (2011
34. Yarlagadda, S. et al. A young Hispanic with c.1646G;A mutation exhibits severe cystic fibrosis lung disease: Is ivacaftor an option for therapy? Am. J. Respir. Crit. Care Med. 186, 694-696 (2012
35. Accurso, F.J. et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N. Engl. J. Med. 363, 1991-2003 (2010
36. Sloane, P.A. et al. A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease. PLoS ONE 7, e39809 (2012
37. Lubamba, B., Dhooghe, B., Noel, S. & Leal, T. Cystic fibrosis: Insight into CFTR pathophysiology and pharmacotherapy. Clin. Biochem. 45, 1132-1144 (2012
38. Kiesewetter, S. et al. A mutation in CFTR produces different phenotypes depending on chromosomal background. Nat. Genet. 5, 274-278 (1993
39. Jurkuvenaite, A. et al. Functional stability of rescued delta F508 cystic fibrosis transmembrane conductance regulator in airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 42, 363-372 (2010
40. He, L. et al. Correctors of ΔF508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein. FASEB J. 27, 536-545 (2013